All CAR-T articles
-
PodcastAdvances in CAR-T cancer therapy & carbon materials’ hidden defects
What does recent success with bladder tumours mean for solid cancer treatment? And we discuss why scientists are rethinking how they assign peaks in spectra of carbon-based materials.
-
ResearchStep forward for CAR-T therapy as it shows promise in solid bladder tumours
Animal tests show targeting bladder cancer specific protein can treat tumours and could cut need for surgery
-
BusinessLife-saving cancer gene therapy under investigation after being linked to rare secondary cancers
US drug agency examining six CAR-T therapies after reports of T-cell malignancies
-
FeatureA decade of CAR-T cell therapy
Nina Notman looks at the revolutionary treatment already taking on cancer, now aiming for wider use
-
NewsData manipulation casts shadows on Novartis gene therapy
Manufacturing problems with other new medicines highlight difficulty of developing advanced treatments
-
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
BusinessJuno CAR-T trial suspended after patient deaths
Immunotherapy study restarted with amended pre-treatment protocol
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
BusinessCompanies clamour for CAR-T
Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field